{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T21:13:20Z","timestamp":1788988400660,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T00:00:00Z","timestamp":1633564800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["heartrhythmopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Rhythm O2"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.hroo.2021.10.002","type":"journal-article","created":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T03:05:38Z","timestamp":1639710338000},"page":"840-847","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"PB","title":["Oral procainamide as pharmacological treatment of recurrent and refractory ventricular tachyarrhythmias: A single-center experience"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1005-7612","authenticated-orcid":false,"given":"Mauro","family":"Toniolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Muser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Grilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Burelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Rebellato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Daleffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Facchin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Imazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hroo.2021.10.002_bib1","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa013474","article-title":"Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. Multicenter Automatic Defibrillator Implantation Trial \u2013 II (MADIT II)","volume":"346","author":"Moss","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hroo.2021.10.002_bib2","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJM199711273372202","article-title":"A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias","volume":"337","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hroo.2021.10.002_bib3","first-page":"e272","article-title":"2017 AHA\/ACC\/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death","volume":"138","author":"Al-Khatib","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.hroo.2021.10.002_bib4","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1093\/eurheartj\/ehv316","volume":"36","author":"Priori","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hroo.2021.10.002_bib5","series-title":"Encyclopedia of Toxicology","first-page":"1070","article-title":"Procainamide","author":"Holstege","year":"2014"},{"key":"10.1016\/j.hroo.2021.10.002_bib6","first-page":"CD008093","article-title":"Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death","volume":"12","author":"Claro","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.hroo.2021.10.002_bib7","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0735-1097(98)00521-X","article-title":"Suppression of sustained ventricular tachyarrhythmias: a comparison of d-I-sotalol with no antiarrhythmic drug treatment","volume":"33","author":"Kuhlkamp","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hroo.2021.10.002_bib8","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0002-9149(99)80717-6","article-title":"Survival with oral d-sotalol in patients with left ventricular dysfunction after myocardial infarction: rationale, design, and methods (the SWORD trial)","volume":"75","author":"Waldo","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hroo.2021.10.002_bib9","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0140-6736(96)09145-3","article-title":"Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators","volume":"349","author":"Julian","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.hroo.2021.10.002_bib10","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.295.2.165","volume":"295","author":"Connolly","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.hroo.2021.10.002_bib11","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/0002-9149(91)90895-R","article-title":"Cardiac arrest in Seattle: conventional versus amiodarone drug evaluation (the CASCADE study)","volume":"67","year":"1991","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hroo.2021.10.002_bib12","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/eurheartj\/ehl478","article-title":"Adjunctive antiarrhythmic drug therapy in patients with implantable cardioverter defibrillators: a systematic review","volume":"28","author":"Ferreira-Gonzalez","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hroo.2021.10.002_bib13","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/acem.13767","article-title":"Procainamide versus amiodarone for stable ventricular tachycardia","volume":"26","author":"Kelson","year":"2019","journal-title":"Acad Emerg Med"},{"key":"10.1016\/j.hroo.2021.10.002_bib14","first-page":"1329","article-title":"on behalf of the PROCAMIO Study Investigators. Randomized comparison of intravenous procainamide vs. intravenous amiodarone for the acute treatment of tolerated wide QRS tachycardia: The PROCAMIO study","volume":"38","author":"Ortiz","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hroo.2021.10.002_bib15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1161\/01.CIR.4.1.13","article-title":"The use of procainamide in cardiac arrhythmias","volume":"4","author":"Kayden","year":"1951","journal-title":"Circulation"},{"key":"10.1016\/j.hroo.2021.10.002_bib16","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1161\/01.CIR.15.1.118","article-title":"Procainamide: a review","volume":"15","author":"Kayden","year":"1957","journal-title":"Circulation"},{"key":"10.1016\/j.hroo.2021.10.002_bib17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1749-6632.1984.tb14519.x","article-title":"Procainamide: clinical pharmacology and efficacy against ventricular arrhythmias","volume":"432","author":"Giardina","year":"1984","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.hroo.2021.10.002_bib18","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/0002-9149(80)90440-3","article-title":"Efficacy, plasma concentrations and adverse effects of a new sustained release procainamide preparation","volume":"46","author":"Giardina","year":"1980","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hroo.2021.10.002_bib19","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1001\/jama.1971.03180220036006","article-title":"Procainamide dosage schedules, plasma concentrations and clinical effects","volume":"215","author":"Koch-Weser","year":"1971","journal-title":"JAMA"},{"key":"10.1016\/j.hroo.2021.10.002_bib20","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1161\/01.CIR.81.3.860","article-title":"Comparative hemodynamic effects of procainamide, tocainide, and encainide in severe chronic heart failure","volume":"81","author":"Gottlieb","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.hroo.2021.10.002_bib21","first-page":"279","article-title":"Prognostic role of NYHA class in heart failure patients undergoing primary prevention ICD therapy","volume":"7","author":"Briongos-Figuero","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.hroo.2021.10.002_bib22","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.hrthm.2009.11.027","article-title":"Differences in effects of electrical therapy type for ventricular arrhythmias on mortality in implantable cardioverter-defibrillator patients","volume":"7","author":"Sweeney","year":"2010","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hroo.2021.10.002_bib23","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/0002-9149(85)90775-1","article-title":"Electropharmacologic testing in sustained ventricular tachycardia associated with coronary heart disease: value of the response to intravenous procainamide in predicting the response to oral procainamide and oral quinidine treatment","volume":"56","author":"Oseran","year":"1985","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hroo.2021.10.002_bib24","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.117.005663","article-title":"Effect of baseline antiarrhythmic drug on outcomes with ablation in ischemic ventricular tachycardia: a VANISH substudy (Ventricular Tachycardia Ablation Versus Escalated Antiarrhythmic Drug Therapy in Ischemic Heart Disease)","volume":"11","author":"Parkash","year":"2018","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.hroo.2021.10.002_bib25","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1161\/hc0602.103675","article-title":"Isthmus characteristics of reentrant ventricular tachycardia after myocardial infarction","volume":"105","author":"de Chillou","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.hroo.2021.10.002_bib26","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1161\/01.CIR.101.11.1288","article-title":"Linear ablation lesions for control of unmappable ventricular tachycardia in patients with ischemic and nonischemic cardiomyopathy","volume":"101","author":"Marchilinski","year":"2000","journal-title":"Circulation"},{"issue":"139","key":"10.1016\/j.hroo.2021.10.002_bib27","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1161\/CIRCULATIONAHA.118.037997","article-title":"Catheter ablation of refractory ventricular fibrillation storm after myocardial infarction","volume":"14","author":"Komatsu","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.hroo.2021.10.002_bib28","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jacep.2021.03.024","article-title":"Quinidine in the management of recurrent ventricular arrhythmias","volume":"7","author":"Li","year":"2021","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.hroo.2021.10.002_bib29","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0140-6736(73)92270-8","article-title":"Treatment of ventricular arrhythmias with mexiletine (K\u00f6 1973)","volume":"2","author":"Talbot","year":"1973","journal-title":"Lancet"},{"key":"10.1016\/j.hroo.2021.10.002_bib30","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/S0140-6736(80)92395-8","article-title":"Oral mexiletine in high-risk patients after myocardial infarction","volume":"2","author":"Chamberlain","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/j.hroo.2021.10.002_bib31","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1513614","article-title":"Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs","volume":"375","author":"Sapp","year":"2016","journal-title":"N Engl J Med"}],"container-title":["Heart Rhythm O2"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666501821001999?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666501821001999?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:27:45Z","timestamp":1762993665000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666501821001999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S2666501821001999"],"URL":"https:\/\/doi.org\/10.1016\/j.hroo.2021.10.002","relation":{},"ISSN":["2666-5018"],"issn-type":[{"value":"2666-5018","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral procainamide as pharmacological treatment of recurrent and refractory ventricular tachyarrhythmias: A single-center experience","name":"articletitle","label":"Article Title"},{"value":"Heart Rhythm O2","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hroo.2021.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Heart Rhythm Society. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}